Literature DB >> 19439471

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.

Bette T Korber1, Norman L Letvin, Barton F Haynes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19439471      PMCID： PMC2738160          DOI： 10.1128/JVI.00114-09

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  101 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences.

Authors:  Laura E Valentine; Shari M Piaskowski; Eva G Rakasz; Nathan L Henry; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

3.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

Authors:  Zhiwei Chen; Yaoxing Huang; Xiuqing Zhao; Lei Ba; Wenyong Zhang; David D Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

5.  Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

Authors:  Walter Jaoko; Frederick N Nakwagala; Omu Anzala; Gloria Omosa Manyonyi; Josephine Birungi; Annet Nanvubya; Farah Bashir; Kirana Bhatt; Hilda Ogutu; Sabina Wakasiaka; Lucy Matu; Wambui Waruingi; Jane Odada; Micah Oyaro; Jackton Indangasi; Jeckonia Ndinya-Achola; Carol Konde; Emmanuel Mugisha; Patricia Fast; Claudia Schmidt; Jill Gilmour; Tony Tarragona; Carol Smith; Burc Barin; Len Dally; Bruce Johnson; Andrew Muluubya; Leslie Nielsen; Peter Hayes; Mark Boaz; Peter Hughes; Tomás Hanke; Andrew McMichael; Job Bwayo; Pontiano Kaleebu
Journal:  Vaccine       Date:  2008-03-31       Impact factor: 3.641

6.  Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.

Authors:  Noah Kiwanuka; Oliver Laeyendecker; Merlin Robb; Godfrey Kigozi; Miguel Arroyo; Francine McCutchan; Leigh Anne Eller; Michael Eller; Fred Makumbi; Deborah Birx; Fred Wabwire-Mangen; David Serwadda; Nelson K Sewankambo; Thomas C Quinn; Maria Wawer; Ronald Gray
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

7.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

8.  Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.

Authors:  Zabrina L Brumme; Chanson J Brumme; David Heckerman; Bette T Korber; Marcus Daniels; Jonathan Carlson; Carl Kadie; Tanmoy Bhattacharya; Celia Chui; James Szinger; Theresa Mo; Robert S Hogg; Julio S G Montaner; Nicole Frahm; Christian Brander; Bruce D Walker; P Richard Harrigan
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

Review 9.  HIV-1 group M conserved elements vaccine.

Authors:  Morgane Rolland; David C Nickle; James I Mullins
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

10.  Crippling HIV one mutation at a time.

Authors:  Todd M Allen; Marcus Altfeld
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307
View more
  83 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 2.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine.

Authors:  Anthony S Fauci; Gregory K Folkers; Hilary D Marston
Journal:  Clin Infect Dis       Date:  2014-09-15       Impact factor: 9.079

4.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

Review 5.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 6.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

7.  Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys.

Authors:  Kathryn E Stephenson; Adam SanMiguel; Nathaniel L Simmons; Kaitlin Smith; Mark G Lewis; James J Szinger; Bette Korber; Dan H Barouch
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

8.  Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.

Authors:  Weimin Chen; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

9.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 10.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.